Vaxcyte
Prix: 47.46Entreprise et modèle économique
Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to address infectious diseases. Its core products include a pipeline of vaccine candidates targeting various pathogens, with a primary emphasis on pneumococcal disease. The company operates within the healthcare sector, primarily generating revenue through research and development activities and potential future product sales.
Profil d’investissement
The investment profile of Vaxcyte is more aligned with growth investors, given its focus on developing new vaccine technologies and the potential for significant future revenue from successful product launches. The stock may appeal to those with a medium to long-term investment horizon, as the company is still in the development phase. Liquidity is moderate, suitable for investors with basic to advanced experience in the biotech sector.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- -6.89 Risque
- Surprise BPA
- -29.7% moins bon que prévu
- Volatilité 20 j
- 3.1% stable
Suivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-06-03 02:49 | Conserver | Vendre | scenario_deterioration |
| 2026-05-28 02:54 | Vendre | Conserver | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-20 02:53 | Conserver | Vendre | scenario_deterioration |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-02-25 19:27 | BTIG | Objectif relevé | — → 89 | 63.04 |
| 2025-11-19 10:23 | Leerink Partners | Objectif relevé | — → 77 | 49.53 |
Rien pour le moment